Systemic use of non-biologic agents in orofacial diseases: other immunomodulatory agents

Systemic non‐biologic agents have long been in clinical use in medicine – often with considerable efficacy, albeit with some adverse effects – as with all medications. With the advent of biologic agents, all of which currently are restricted to systemic use, there is a growing need to ensure which a...

Full description

Saved in:
Bibliographic Details
Published in:Oral diseases 2015-04, Vol.21 (3), p.273-282
Main Authors: Georgakopoulou, EA, Scully, C
Format: Article
Language:English
Subjects:
Anti-Infective Agents - therapeutic use
calcineurin inhibitors
Calcineurin Inhibitors - pharmacology
Calcineurin Inhibitors - therapeutic use
colchicine
Colchicine - pharmacology
Colchicine - therapeutic use
cyclophosphamide
Cyclophosphamide - pharmacology
Cyclophosphamide - therapeutic use
Cyclosporine - therapeutic use
dapsone
Dapsone - pharmacology
Dapsone - therapeutic use
Drug Interactions
Drug Monitoring
Facial Dermatoses - drug therapy
Humans
immunomodulatory agents
Immunosuppressive Agents - therapeutic use
Mouth Diseases - drug therapy
Oral diseases
orofacial diseases
Pharmacology
Psoriasis
Steroids
Tacrolimus - therapeutic use
thalidomide
Thalidomide - pharmacology
Thalidomide - therapeutic use
Tubulin Modulators - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic non‐biologic agents have long been in clinical use in medicine – often with considerable efficacy, albeit with some adverse effects – as with all medications. With the advent of biologic agents, all of which currently are restricted to systemic use, there is a growing need to ensure which agents have the better therapeutic ratio. The non‐biologic agents (NBAs) include a range of agents, most importantly the corticosteroids (steroids). Previous articles by us in this series have discussed systemic use of corticosteroids and purine synthesis inhibitors; the other immunomodulating agents (calcineurin inhibitors, thalidomide, dapsone, colchicine and cyclophosphamide) are reviewed in this final article.
ISSN:1354-523X
1601-0825
DOI:10.1111/odi.12172